Stocks and Investing
Stocks and Investing
Wed, November 2, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Andreas Argyrides Maintained (UBX) at Buy with Increased Target to $36 on, Nov 2nd, 2022
Andreas Argyrides of Wedbush, Maintained "Unity Biotechnology, Inc." (UBX) at Buy with Increased Target from $4 to $36 on, Nov 2nd, 2022.
Andreas has made no other calls on UBX in the last 4 months.
There are 2 other peers that have a rating on UBX. Out of the 2 peers that are also analyzing UBX, 0 agree with Andreas's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Andreas
- Salim Syed of "Mizuho" Maintained at Strong Buy with Increased Target to $80 on, Tuesday, August 16th, 2022
- Yigal Nochomovitz of "Citigroup" Maintained at Strong Buy with Increased Target to $80 on, Monday, August 15th, 2022
Contributing Sources